Overview |
bs-9393R |
CAF1p55 Polyclonal Antibody |
WB, IHC-P, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human CAF1p55 |
221-320/1507 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
9730 |
Caf 1; CAF-1; CAF-1 P55 subunit; CAF1 p55 subunit; CAF1A; CAF1P55; chaf1b; Chromatin assembly factor 1 p55 subunit; Chromatin assembly factor 1 p60 subunit; chromatin assembly factor 1 subunit; Chromatin assembly factor I; dCAF-1; dCAF1; Human chromatin assembly factor-I p55 subunit; Nucleosome remodeling factor 55 kDa subunit; NURF 55; NURF-55; p55; Probable histone binding protein Caf1; VPRBP_HUMAN. |
P55 is an extensively palmitoylated erythrocyte membrane protein, and a member of the MAGUK family. P55 also resists salt extraction, resulting in a high affinity for the plasma membrane. P55 contains a PDZ/DHR domain, a conserved SH-3 domain that appears to suppress tyrosine kinase activity of various oncoproteins, a 39-amino acid motif that binds to cytoskeletal protein 4.1R, and a guanylate kinase-like domain. Interaction with glycophorin C (GPC) and 4.1R suggests that p55 may play a role in the dynamic regulation in the erythrocyte membrane. In addition, p55 gene expression in vivo may be associated with a CpG island. P55 is constitutively expressed in K562 erythroleukemia cells during erythropoiesis and undergoes a 2-fold amplification after induction. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |